AIM ImmunoTech Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIM research report →
Companyaimimmuno.com
AIM ImmunoTech Inc. , an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts.
- CEO
- Thomas K. Equels
- IPO
- 1995
- Employees
- 21
- HQ
- Ocala, FL, US
Price Chart
Valuation
- Market Cap
- $861.44K
- P/E
- -0.08
- P/S
- 9.16
- P/B
- 0.52
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -132.98%
- Op Margin
- -10839.36%
- Net Margin
- -14123.40%
- ROE
- 261.84%
- ROIC
- -152.10%
Growth & Income
- Revenue
- $88.00K · -48.24%
- Net Income
- $-13,958,000 · 19.41%
- EPS
- $-8.62 · 23.20%
- Op Income
- $-10,526,000
- FCF YoY
- 26.49%
Performance & Tape
- 52W High
- $19.74
- 52W Low
- $0.21
- 50D MA
- $0.58
- 200D MA
- $1.48
- Beta
- 1.24
- Avg Volume
- 11.60M
Get TickerSpark's AI analysis on AIM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 12, 26 | Equels Thomas K | other | 25,000 |
| Mar 12, 26 | Equels Thomas K | other | 25 |
| Mar 12, 26 | CHEMEROW DAVID I. | other | 25,000 |
| Mar 12, 26 | CHEMEROW DAVID I. | other | 25 |
| Mar 6, 26 | Equels Thomas K | other | 50,000 |
| Mar 6, 26 | Equels Thomas K | other | 25 |
| Mar 6, 26 | CHEMEROW DAVID I. | other | 50,000 |
| Mar 6, 26 | CHEMEROW DAVID I. | other | 25 |
| Feb 5, 26 | CHEMEROW DAVID I. | other | 2,800 |
| Jul 17, 25 | KELLNER TED D | other | 0 |
Our AIM Coverage
We haven't published any research on AIM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AIM Report →